Literature DB >> 11059907

Cytokine production in unmedicated and treated schizophrenic patients.

M Rothermundt1, V Arolt, J Leadbeater, M Peters, S Rudolf, H Kirchner.   

Abstract

Recent findings have strengthened the hypothesis that immunological dysfunctions may contribute towards the multifactorial pathogenesis of schizophrenia. The validity of these findings is questioned by the fact that most studied subjects have received potentially immunomodulatory medication upon investigation. In order to rule out such confounding effects, 24 initially unmedicated acutely ill schizophrenic patients were studied immunologically and psychiatrically (PANSS) before and during 4 weeks of neuroleptic treatment. The production of IFN-gamma was decreased upon admission and after 2 weeks of treatment compared to matched healthy controls. No differences in IL-2 and IFN-gamma production between unmedicated and medicated states were observed. These results do not support the notion that neuroleptic medication in vivo might influence TH1 cytokine production in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059907     DOI: 10.1097/00001756-200010200-00024

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  6 in total

1.  Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR).

Authors:  Oliver Freudenreich; Mark A Brockman; David C Henderson; A Eden Evins; Xiaoduo Fan; Jared P Walsh; Donald C Goff
Journal:  Psychiatry Res       Date:  2010-02-04       Impact factor: 3.222

2.  Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia.

Authors:  Mark H Rapaport; Catherine Bresee
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 3.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

4.  Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment.

Authors:  A B Erbağci; H Herken; O Köylüoglu; N Yilmaz; M Tarakçioglu
Journal:  Mediators Inflamm       Date:  2001-06       Impact factor: 4.711

5.  Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis.

Authors:  Laura K Green; Pirooz Zareie; Nikki Templeton; Robert A Keyzers; Bronwen Connor; Anne Camille La Flamme
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-03-17

6.  Comparison of peripheral and central schizophrenia biomarker profiles.

Authors:  Laura W Harris; Sandra Pietsch; Tammy M K Cheng; Emanuel Schwarz; Paul C Guest; Sabine Bahn
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.